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Background: Oxidative stress and glutathione (GSH) metab-
olism dysregulation has been implicated in the pathophysi-
ology of schizophrenia. GAG-trinucleotide repeat (TNR) 
polymorphisms in the glutamate-cysteine ligase catalytic 
gene (GCLC), the rate-limiting enzyme for GSH synthesis, 
are associated with schizophrenia. In addition, GSH may 
serve as a reserve pool for neuronal glutamate (Glu) through 
the γ-glutamyl cycle. The aim of this study is to investigate 
brain [GSH] and its association with GCLC polymorphism, 
peripheral redox indices and brain Glu. Methods: Magnetic 
resonance spectroscopy was used to measure [GSH] and 
[Glu] in the medial prefrontal cortex (mPFC) of 25 early-
psychosis patients and 33 controls. GCLC polymorphism 
was genotyped, glutathione peroxidases (GPx) and gluta-
thione reductase (GR) activities were determined in blood 
cells. Results: Significantly lower [GSHmPFC] in GCLC 
high-risk genotype subjects were revealed as compared to 
low-risk genotype subjects independent of disease status. In 
male subjects, [GSHmPFC] and blood GPx activities correlate 
positively in controls (P = .021), but negatively in patients 
(P = .039). In GCLC low-risk genotypes, [GlumPFC] are lower 
in patients, while it is not the case for high-risk genotypes. 
Conclusions: GCLC high-risk genotypes are associated 
with low [GSHmPFC], highlighting that GCLC polymor-
phisms should be considered in pathology studies of cerebral 
GSH. Low brain GSH levels are related to low peripheral 
oxidation status in controls but with high oxidation status 
in patients, pointing to a dysregulated GSH homeostasis in 
early psychosis patients. GCLC polymorphisms and disease 
associated correlations between brain GSH and Glu levels 
may allow patients stratification.
Key words:  schizophrenia/glutathione/oxidative stress/
MRS/GCLC/glutamate/redox/glutathione peroxidase
Introduction
Schizophrenia is a major psychiatric disorder which 
results from a complex interplay between genetic and 
environmental risk factors during neurodevelopment. 
There is increasing evidence suggesting that oxidative 
stress and dysregulation of the glutathione (GSH) metab-
olism play a role in the pathophysiology of the disease.1–5 
GSH serves as a major cellular redox regulator and anti-
oxidant protecting cell from damages induced by reac-
tive oxygen species. Decreased [GSH] have been reported 
in cerebro-spinal fluid (−27%) of patients with chronic 
schizophrenia.6 A  “postmortem” study also revealed 
lower caudate [GSH] in treated patients than in con-
trol subjects.7 Furthermore, similar reduction of [GSH] 
was observed in blood plasma of treated and untreated 
patients.8–11
Studies of cerebral [GSH] in vivo in schizophrenia 
are limited and exclusively achievable by using 1H mag-
netic resonance spectroscopy (MRS). Do et al reported 
a 52% reduction of [GSH] in medial prefrontal cortex of 
chronic schizophrenia patients at 1.5T (14 controls and 
14 patients, in Do et al6; extended to 18 controls and 20 
patients, unpublished results). However, 2 consecutive 
studies in schizophrenia patients did not reveal signifi-
cant GSH alterations in the anterior cingulate cortex at 
4T (9 controls and 11 patients)12 or in posterior medial 
frontal cortex at 3T (16 controls and 20 patients), though 
low [GSH] in this later region were associated with more 
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severe negative symptoms.13 Reasons for such inconsis-
tencies remain unclear. Differences in methodological 
aspects, such as magnetic field strengths, pulse sequences, 
number of subjects, and stage of disease may be relevant.
Whether alterations of cerebral [GSH] are already pres-
ent in the early phase of psychosis (EP) remains an open 
question. Only 1 study has reported 22% higher [GSH] in 
medial temporal lobe of first episode patients using PRESS 
1H MRS sequence at 3T.14 However, the mean Cramer-Rao 
lower-bound (CRLB) for the corresponding measurement 
of GSH was moderately high (~21%). Therefore, further 
investigations of cerebral [GSH] in EP patients including 
those in other brain regions are required.
One genetic factor has been reported to influence 
[GSH] in the periphery: a GAG trinucleotide repeat 
(TNR) polymorphism in the gene coding for the catalytic 
(GCLC) subunit of glutamate-cysteine ligase (GCL), the 
rate-limiting enzyme for GSH synthesis. Importantly, 
this polymorphism was associated with schizophrenia in 
2 case-control studies15: the GCLC high-risk genotypes 
(ie, with 7/8, 8/8, 8/9 and 9/9 TNR) were more frequent 
in patients (30%) and were associated with lower GCLC 
protein expression, GCL activity and [GSH] in fibro-
blasts when challenged with oxidative stress conditions, 
as compared with GCLC low-risk genotypes (ie, with 
7/7 and 7/9 TNR). However, the peripheral GSH levels 
may not reflect GSH status in the central nervous sys-
tem and the association between cerebral GSH levels and 
GCLC polymorphism has never been investigated. The 
understanding of their relation may shed light on current 
discrepancies concerning cerebral [GSH] in psychotic 
patients.
Studies on the various antioxidant systems in the 
peripheral tissue of schizophrenia patients showed large 
discrepancies.1,4 Altered levels of scavenging antioxidant 
enzymes were reported, however with mixed results.16 
Glutathione peroxidases (GPx) are important antioxi-
dant enzymes that eliminate hydrogen and lipid peroxides 
by converting GSH into oxidized GSH (GSSG). Then 
GSSG is reduced back to GSH by glutathione reductase 
(GR; supplementary figure 1s). The precise quantification 
of blood GSH/GSSG balance in a psychiatric clinical 
setting is quite challenging and subjected to artefactual 
oxidations leading to unreliable results.16 To capture the 
(dys)regulation of redox status, we assessed enzymatic 
activities of GPx and GR, as well as their ratio (GPx/
GR) in blood cells instead of GSH/GSSG ratio.
Besides its antioxidant properties, the tripeptide GSH 
has been proposed to constitute a reserve pool for neu-
ronal glutamate (Glu) through the γ-glutamyl cycle.17 
γ-glutamyltranspeptidase (GGT) transfers γ-glutamyl 
moiety of extracellular GSH to an acceptor amino 
acid, generating γ-glutamyl amino acid and cysteinyl-
glycine. On the one side, the cysteinylglycine can then 
provide substrates to synthesize GSH; on the other side, 
γ-glutamyl amino acid can be metabolized to amino acid 
and 5-oxoproline, which can be further catalyzed by the 
5-oxoprolinase to form Glu, a precursor of GSH.18,19 The 
inhibition of 5-oxoprolinase reduces [Glu] in cortical and 
hippocampal neurons, with no changes in [GSH].17 This 
mechanism is of high interest in the context of the glu-
tamatergic hypothesis in schizophrenia,20 and has never 
been evaluated in vivo in humans.
Therefore, the aims of this study were (1) to assess 
[GSH] in medial prefrontal cortex of early psychosis 
patients relative to control subjects, (2) to test its associa-
tion with GAG-TNR of GCLC genotypes and (3) with 
peripheral GSH redox indices (GPx, GR activities and 
their ratio GPx/GR) and finally, (4) to investigate the 
relationship between brain GSH and Glu.
Methods and Materials
Subjects
Twenty-five early psychosis patients (within the first 
3 years of treatment for a psychotic disorder and having 
met psychosis threshold according to the Comprehensive 
Assessment of At Risk Mental States criteria)21 were 
recruited from the Treatment and Early Intervention 
in Psychosis Program (TIPP, University Hospital of 
Lausanne, Lausanne, Switzerland).22 Medication pre-
scribed to patients followed international recommenda-
tions for early psychosis treatment,23 was recorded in 
the medical file and adherence to treatment was rated by 
clinicians. CPZ equivalents were calculated on the basis 
of formulas using regression with power transformation 
suggested by Andreasen et  al24 and of maximum daily 
doses25 for the remaining medication (table 1).
Onset of illness was defined as the time when a defi-
nite diagnosis of psychosis was reached by the presence 
of clear evidence of delusions, hallucinations, first rank 
symptoms, catatonic symptoms for at least 1 week on the 
basis of elements gathered by treating psychiatrist and case 
managers through interviews with patients, their relatives 
and any mental health professional who would have been 
involved in the care of the patient at that time. Duration 
of illness was defined as the time that elapsed between 
onset of illness and the time when MRI was performed. 
Diagnosis for patients was based on DSM-IV criteria and 
is the result of an expert consensus procedure based on 
information gathered over the 3 years of treatment.
Thirty-three age-, sex-matched healthy controls were 
recruited and assessed by the Diagnostic Interview for 
Genetic Studies26 with the following exclusion criteria: 
having major mood, psychotic, or substance-use dis-
order and a first-degree relative with a psychotic disor-
der. Neurological disorder and severe head trauma were 
exclusion criteria for all subjects. Demographic and clini-
cal details of all participants are shown in table  1. All 
participants gave informed written consent prior to par-
ticipate in this study which was approved by the ethics 
review board of the Lausanne University Hospital.
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1H Magnetic Resonance Spectroscopy
All MRS measurements were carried out on a 3T MR 
scanner (Magnetom TimTrio, Siemens Healthcare) with 
a transverse electromagnetic (TEM 3000) head coil (MR 
Instruments, Inc). The magnetic field homogeneity was 
optimized by adjusting first- and second-order shims using 
FAST(EST)MAP.27,28 In vivo 1H MR spectra were acquired 
from a volume of interest (VOI = 20 × 20 × 25 mm3) posi-
tioned in the medial prefrontal cortex (mPFC; figure 1A) 
using a short-TE spin-echo full-intensity acquired local-
ized single voxel spectroscopy technique (SPECIAL).29,30 
The following scan parameters were used: echo time/
repetition time (TE/TR)  =  6/4000 ms, acquisition band-
width  =  2 kHz, number of averages  =  148, vector 
size = 2048. Outer volume suppression (OVS)31 and water 
suppression with variable-pulse power and optimized 
relaxation delays (VAPOR)32 were applied prior to the 
SPECIAL localization sequence.
In addition, to evaluate tissue composition inside the 
VOI, 3-dimensional T1-weighted anatomical images were 
obtained using a magnetization-prepared rapid gradient-
echo (MPRAGE) sequence33 with a 32-channel head array 
coil, TE/TR  =  2.98/2300 ms, inversion time  =  900 ms, 
flip angle  =  9°, field of view  =  240 × 256 mm2, 
matrix = 240 × 256, slice thickness = 1.2 mm.
Spectral Quantification
To obtain [GSHmPFC] and [GlumPFC], water suppressed in 
vivo 1H MR spectra were analyzed by LCModel (Stephen 
Provencher, Inc)34 as a linear combination of model spectra 
provided in a basis-set consisting of 20 simulated individual 
metabolite spectra: alanine (Ala), aspartate (Asp), phospho-
creatine (PCr), creatine (Cr), γ-aminobutyric acid (GABA), 
glutamine (Gln), Glu, phosphorylcholine (PCho), glyc-
erophosphorylcholine (GPC), GSH, glucose (Glc), lactate 
(Lac), glycine (Gly), myo-inositol (mIns), N-acetylaspartyl-
glutamate (NAA), N-acetylaspartylglutamate (NAAG), 
ascorbate (Asc), phosphoryl-ethanolamine (PE), scyllo-
inositol (Scyllo), taurine (Tau), and an experimentally mea-
sured macromolecule baseline.35 The errors of calculated 
concentrations obtained from the fit are shown by CRLBs. 
Unsuppressed water 1H MR spectra were used as an internal 
reference for the quantification of metabolite concentrations. 
The spectral range for analysis was set to 0.2–4.2 ppm. Tissue 
composition inside the VOI was calculated based on the seg-
mentation of 3D T1-weighted anatomical images using an 
in-house software.36 Water concentrations, used in LCModel 
analysis, were calculated based on the volume fractions of 
white matter (WM), grey matter (GM), and cerebrospinal 
fluid (CSF) assuming water concentrations of WM, GM, 
and CSF are 35880, 43300, and 55556 mM, respectively. 
Metabolite concentrations were then divided by the frac-
tion of WM and GM to correct for CSF inside the VOI, 
since metabolites are mainly present in WM and GM.37 The 
signal-to-noise ratio (SNR) was obtained using NAA peak 
height at 2.01 ppm divided by the SD of the noise.
Genotyping of GCLC Tri-nucleotide Polymorphism
DNA was extracted from whole blood. PCR was per-
formed according to Walsh et  al38 and modified as 
in Gysin et  al15: in a 20 μL reaction mix with GoTaq 
Table 1. Demographic Characteristics of Controls and Early Psychosis Patients
Controls (n = 33) Patients (n = 25) P Value
Age, years (mean ± SD) 25.4 ± 4.5 24.8 ± 6.1 n.sa
Sex, Male/Female 18/15 18/7 n.sb
Ethnicity Caucasian Caucasian —
Education of parents, years (mean ± SD) 14.4 ± 3.6 15.1 ± 4.6 n.sa
Cigarettes, smokers/nonsmokers 4/29 13/12 .001b
Handedness, Right/Left/Ambidextrous 28/5/0 22/2/1 n.sc
Illness duration, days (mean ± SD) — 933 ± 867 —
CPZ equivalents, mg (mean ± SD) — 325 ± 317d —
Antipsychotic medications
 Amisulpride 3
 Aripiprazole 5
 Clozapine 1
 Olanzapine 2
 Paliperidone 1
 Quetiapine 5
 Risperidone 3
 None 5
Note: CPZ equivalents, chlorpromazine equivalents; n.s., not significant (P > .05).
aUnpaired 2-tailed Student t test.
bChi-square.
cFisher’s exact test.
dFive patients without antipsychotic medication.
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polymerase, 1.5 mM MgCl2, 0.25 μM of each primer (for-
ward: TTCTGCGGGCGGCTGAGTGTCC; reverse: 
ATGGCGCTTGGTTTCCTCCC), 0.2 mM of dNTP 
and 100ng of  genomic DNA. Amplification temperature 
were: 95° for 2 minutes followed by 32 cycles of  95° for 30 
seconds, 62° for 30 seconds, 72° for 1 minute and 1 step at 
72° for 5 minutes. PCR products were separated on 10% 
polyacrylamide gels and were visualized under UV after 
15 minutes staining in GelRed solution. Classification 
into GCLC high- or GCLC low-risk genotype is based 
on the number of  GAG repeats as defined in Gysin et al15 
(7/8, 8/8, 8/9, 9/9 and 7/7, 7/9 respectively).
Fig. 1. (A) T1-weighted MPRAGE images with the volume of interest (20 × 20 × 25 mm
3) for magnetic resonance spectroscopy (MRS) 
in the medial prefrontal cortex. (B) A representative 1H MR spectrum acquired with the SPECIAL sequence at 3T (TE/TR = 6/4000 ms, 
number of averages = 148), the corresponding LCModel spectral fit, fit residual, macromolecules, baseline and individual metabolite fits 
including glutathione (GSH).
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[GSHB], GPx and GR Enzymatic Activities in Blood
Blood was collected by venipuncture in Vacutainer-tubes 
coated with Li-heparinate (Becton Dickinson), between 
7 AM and 8:30 AM under restricted activity conditions 
and fasting from the previous midnight. An aliquot of 
whole blood is sampled and frozen at −80°C until analy-
sis of [GSHB]. [GSHB] was measured in 45 μL of whole 
blood using a diagnostic kit and according to manufac-
turer instructions (Calbiochem); [GSHB] are normalized 
to blood volume. Blood cells were prepared as in Gysin 
et  al15. All manipulations were performed rapidly with 
cooling to avoid artefactual oxidation of thiol com-
pounds. Essentially, GR activity39 was assessed in 8 μL 
of hemolyzed blood incubated in a phosphate buffer 
solution (100 mM, pH 7.5) with EDTA (0.6 mM), oxi-
dized glutathione (2.5 mM), NADPH (0.25 mM). GPx 
activity40 was assessed in 8μL of hemolyzed blood incu-
bated in phosphate buffer solution (100 mM, pH 7.5) 
with EDTA(0.6 mM), glutathione (2.5 mM), NADPH 
(0.25 mM), GR (0.84 U/ml; Fluka) and Tert-butyl hydro-
peroxide (0.8 mM, Fluka). Enzymatic activities were 
determined in triplicates as a function of the decrease in 
NADPH measured at 340 nm and normalized to hemo-
globin content.
Statistical Analysis
Differences between patients and controls in sex, smok-
ing and handedness were assessed using Chi-square test 
or Fisher’s exact test accordingly. Differences in age, 
education of parents, fractions of WM, GM and CSF, 
spectral quality (SNR and linewidth) between patients 
and controls, [GSHmPFC] between smokers and non-
smokers were evaluated by unpaired t test (2-tailed). 
The effects of GCLC GAG-TNR polymorphism (low-
risk vs high-risk), disease (controls vs patients), sex 
(male vs female) and age on [GSHmPFC], [GSHB], blood 
GPx and GR activities were investigated using general-
ized linear model in Matlab (R2013b,The MathWorks, 
Inc). Two-tailed Mann-Whitney test was used to inves-
tigate the alterations in [GlumPFC] and the difference of 
[GSHmPFC] between medicated and unmedicated patients. 
All correlation tests were performed using the Spearman 
rank correlation (2-tailed) in GraphPad Prism (Version 
5.04, GraphPad Software, Inc). The difference between 
2 independent correlation coefficients was tested online 
(Calculation for the test of the difference between 2 inde-
pendent correlation coefficients is available from http://
quantpsy.org).
Results
There were no statistical differences in age, sex, hand-
edness and education of parents between patients and 
controls indicating a good matching for these criteria 
(table 1). All individuals were Caucasian. Since the high 
prevalence of smoking in schizophrenia patients,41 we 
also observed more smokers in patients.
A representative short-TE 1H MR spectrum obtained 
from mPFC, LCModel spectral fit and individual metab-
olites fits are shown in figure 1B. [GSHmPFC] and [GlumPFC] 
were measured by short-TE 1H MRS at 3T and quantified 
using LCModel yielding CRLBs of 10 ± 3% and 2.0 ± 0.5% 
(mean ± SD), respectively. In addition, other 11 metabo-
lites were quantified from LCModel fitting including Asp, 
Cr, PCr, Gln, Ins, NAA, total Choline (GPC+PCho) with 
mean CRLBs < 10% and GABA, Lac, PE, Tau with mean 
CRLBs < 20%. Spectral SNR and linewidth (LCModel 
output) were 104 ± 16, 0.031 ± 0.005 ppm for controls 
and 97 ± 12, 0.033 ± 0.006 ppm for patients, respectively. 
No significant differences (P > .05) in spectral quality 
(ie, SNR and linewidth) between groups were observed. 
Tissue compositions inside the MRS voxel were mea-
sured and there is no differences of WM, GM and CSF 
fractions between patients and controls (supplementary 
table 1s).
GSH Levels in mPFC
To discern [GSHmPFC] changes in early psychosis and its 
association with GCLC polymorphism, GCLC geno-
types were included as a covariant together with age and 
sex to test whether [GSHmPFC] were different between 
25 EP patients and 33 controls. There were significantly 
lower [GSHmPFC] in subjects with the GCLC high-risk 
genotypes (1.15 ± 0.17 μmol/g) as compared to those with 
low-risk genotypes (1.34 ± 0.25μmol/g; P = .006; figure 2), 
independent of the disease status (P > .05), age (P > .05) 
and sex (P > .05). To study the potential effect of medi-
cation, illness duration and smoking, we first correlated 
[GSHmPFC] with CPZ equivalents and disease duration. 
Fig. 2. [GSHmPFC] are lower in glutamate-cysteine ligase catalytic 
gene (GCLC) high-risk genotypes (7/8, 8/8, 8/9 and 9/9; n = 17) 
than in low-risk genotypes (7/7 and 7/9; n = 41). From left to 
right: [GSHmPFC] in low-risk genotype controls, low-risk genotype 
patients, high-risk genotype controls and high-risk genotype 
patients, respectively. Each horizontal bar indicates the mean 
value of the group. **P = .006.
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No significant correlations were found between them 
(P > .05). [GSHmPFC] were further compared between 
smokers and non-smokers, no significant difference was 
revealed (P > .05). Including smoking as one covariant 
showed no effect on the result and [GSHmPFC] associa-
tion with GCLC polymorphism still remained significant 
(P = .006).
To decipher whether blood GSH reflects cerebral GSH, 
we studied the relationship between them. No correlation 
was found between [GSHB] and [GSHmPFC] (supplemen-
tary figure 2s) and [GSHB] were not affected by disease, 
age, sex, and GCLC polymorphism (supplementary 
table 2s).
Relationship Between [GSHmPFC] and [GlumPFC]
We revealed that [GSHmPFC] were affected by GCLC poly-
morphism and additionally GSH may serve as a reservoir 
for neuronal Glu,17 which is involved in the NMDA recep-
tor hypofunction hypothesis of schizophrenia. Therefore, 
we evaluated [GlumPFC] between patients and controls 
in GCLC low-risk and high-risk group respectively and 
revealed a 8% reduction of [GlumPFC] in GCLC low-risk 
patients relative to low-risk controls (P = .01), while no 
difference was found between high-risk genotypes in con-
trols and patients (figure 3A). In GCLC low-risk controls, 
[GlumPFC] positively correlated with [GSHmPFC] (r = .5133, 
P = .010; figure 3B); however this correlation was absent 
in low-risk genotype patients. Interestingly, correlations 
were observed neither in controls nor in patients with 
high-risk genotypes (figure 3C).
Correlation Between Brain GSH and Peripheral Redox 
Enzymatic Activities
To test the association between cerebral GSH and periph-
eral redox indices, we investigated enzymatic activities of 
GPx and GR in blood cells, and their correlations with 
[GSHmPFC]. No significant differences were observed for 
GPx and GR activities between patients and controls, nor 
between GCLC high-risk and low-risk genotype (supple-
mentary table  2s). Female subjects showed higher GR 
activities than male subjects (P  =  .015, supplementary 
table 2s), which is consistent with,42 therefore, following 
analyses were performed separately for each sex group.
[GSHmPFC] were positively correlated with GPx activi-
ties in male controls (figure  4A; r  =  .5543, P  =  .021). 
In contrast, in male patients an inverse correlation was 
obtained between [GSHmPFC] and GPx activities (fig-
ure 4D; r = −.4899, P = .039). There is a trend of a posi-
tive correlation between GR activities and [GSHmPFC] in 
male controls (figure 4B; r = .3973, P = .114) but not in 
male patients (figure 4E; r = .0111, P = .966). The ratio of 
GPx/GR activity, which reflects the regulation of redox 
status, tends to correlate negatively with [GSHmPFC] in 
male patients (figure 4F; r = −.4760, P = .0534), whereas 
such correlation was absent in male controls (figure 4C). 
We further tested the significance of the difference 
between patients and controls for the correlation coeffi-
cients of [GSHmPFC] with GPx activities, and with GPx/
GR ratio. Patients and controls demonstrated significant 
differences in correlation coefficients of [GSHmPFC] with 
GPx activities (z  =  2.07, P  =  .002) and with GPx/GR 
ratio (z = 2.18, P = .029). For female controls or patients, 
we did not observe any significant correlations (supple-
mentary figure 3s).
Discussion
In this study, we assessed [GSHmPFC] of 25 early psy-
chosis patients and 33 control subjects. We showed that 
GAG-TNR polymorphisms in GCLC, which have been 
previously linked to schizophrenia, are associated with 
[GSHmPFC] irrespectively of disease status. Additional 
analyses also revealed that correlation between cortical 
GSH levels and peripheral redox marker, ie, blood cells 
GPx enzymatic activities, differed in patients and con-
trols: their correlation is positive in controls and nega-
tive in patients. Low [GSHmPFC] are associated with low 
peripheral oxidation status in controls but with high 
Fig. 3. (A) [GlumPFC] in glutamate-cysteine ligase catalytic gene (GCLC) low-risk controls (n = 24), low-risk patients (n = 17), high-risk 
controls (n = 9) and high-risk patients (n = 8). The bars represent mean values of each data group. *P = .010. Different associations 
between [GSHmPFC] and [GlumPFC] in GCLC low-risk (B) and high-risk (C) subjects. In GCLC low-risk controls, [GSHmPFC] positively 
correlated with [GlumPFC]. The correlations between [GSHmPFC] and [GlumPFC] were absent in GCLC low-risk patients, high-risk controls 
and high-risk patients.
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oxidation status in patients, suggesting a dysregula-
tion of GSH homeostasis under oxidative conditions. 
Furthermore, in GCLC low-risk genotypes, [GlumPFC] are 
lower in patients as compared to controls, while it is not 
the case for GCLC high-risk genotypes. This suggests a 
predominant pathogenic role of glutamatergic system 
impairments in GCLC low-risk genotypes.
In vivo Measurement of Cerebral GSH
The in vivo measurement of GSH concentration in human 
brain using (short-TE) 1H MRS is challenging because of 
its low concentration and strong spectral overlap mainly 
with resonances eg, originated from glutamate and glu-
tamine. Therefore, spectral editing schemes43–45 combined 
with localization sequences have been developed for the 
detection of GSH. Although an editing approach pro-
vides a resolved measurement of GSH, several down-
side aspects remain, such as signal reduction induced by 
editing efficiency,44 sensitive editing performance to the 
frequency drift of the narrow band editing pulse,46 T2 
relaxation assumption for quantification and restricted 
number of measureable metabolites.44 As an alternative 
approach, short-TE MRS has been employed to detect 
GSH at 3T and above.12,29,47,48 The main benefit of short-
TE MRS, apart from GSH measurement, is the possibility 
to simultaneously assess a large number of metabolites. 
Nevertheless, due to spectral overlap, GSH quantifica-
tion relies on deconvolution methods such as LCModel.34 
In the current study, we performed GSH measurement 
Fig. 4. Correlations between [GSHmPFC] and blood redox enzymatic activities of glutathione peroxidases (GPx), glutathione reductase 
(GR) and ratio GPx/GR in male controls (n = 17) and in male patients (n = 17). [GSHmPFC] were positively correlated with GPx activities 
in controls (A). Conversely, in patients [GSHmPFC] were negatively correlated with GPx activities (D). There is a trend of positive 
correlation between GR activities and [GSHmPFC] in controls (B) but not in patients (E). The ratio of GPx/GR activity, reflecting the 
regulation of redox status, tends to correlate negatively with [GSHmPFC] in patients (F) not in controls (C).
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by short-TE 1H-MRS to obtain other metabolic infor-
mation, eg, Glu, in parallel. A previous validation study 
of Terpstra et  al12 compared GSH measurements using 
both, MEGA-PRESS and short-TE STEAM methods, at 
4T and demonstrated a good agreement between these 2 
methods. Recently, Wijtenburg et al48 showed an excellent 
reproducibility of GSH measurement using short-TE 
MRS at 3T. We further evaluated the accuracy and preci-
sion of GSH measurement by the short-TE MRS method 
at 3T showing that comparable spectral quality in terms 
of SNR and linewidth would allow the accurate measure-
ment of GSH changes between groups.49 Therefore, the 
matched spectral quality is a prerequisite for the detec-
tion of GSH alterations. This requirement was well satis-
fied in this work as judged from equivalently high spectral 
quality of both patient and control groups.
Association of [GSHmPFC] With GCLC Polymorphism
The current study provided the original finding that 
GCLC high-risk genotypes are associated with low 
[GSHmPFC]. The functional impact of short GAG repeats 
on GCLC regulation is still being debated: at the molec-
ular level, a recent study suggested that the length of 
the TNR modulates mRNA translation,50 but it is con-
troversial whether longer repeats increase or decrease 
GCLC and subsequently GSH levels. Interestingly, 
Nichenametla et al suggest that the effect might be cell 
and tissue specific. Indeed, in vitro,50 in tumor cell lines,51 
and in mononuclear blood cells,50 the 7/7 genotype (ie, 
GCLC low-risk) is associated with low GSH and low 
GCL activity as compared to 9/9 genotype (ie, GCLC 
high-risk). But in other systems, such as red blood cells 
or fibroblasts, submitted to oxidative stress the regulation 
is opposite: 7/7 genotype display more GSH and higher 
GCL activity than 9/9 genotype.15,50,52 Similarly, we now 
show that GCLC low-risk genotypes (7/7 and 7/9) are 
associated with higher [GSHmPFC] than high-risk geno-
types (9/9, 8/8, 8/9, 7/8). Therefore, our study highlights 
which type of regulation is linked with GAG repeats in 
cerebral cortex. Since GCLC high-risk genotypes were 
more frequent in patients,15 this result may thus clarify 
the potential implication of GCLC high-risk genotypes 
in psychiatric diseases.
In addition, this polymorphism in GCLC could be a 
plausible reason for not revealing [GSHmPFC] changes in 
the patient cohort of the current study, ie, group differ-
ences depend on the proportion of the various GAG-
TNR genotypes. Indeed, in contrast to the larger cohort 
of patients with chronic schizophrenia previously studied, 
in which the GCLC high-risk genotypes were more fre-
quently observed in the disease group,15 this is not the case 
for the present small sample in which the percentage of 
high-risk controls subjects (27%) was similar to that of EP 
patients (31%). Importantly, this could thus be an explana-
tion for inconsistent results observed for brain GSH levels 
in schizophrenia patients, ie, essentially different GAG-
TNR genotypes distribution in the very small cohorts of 
previous studies leading to discrepancies. In this regard, it 
is important to note that allele frequencies vary strongly 
with the ethnic background and therefore not control-
ling for this factor may induce bias.52,53 In the context of 
a redox dysregulation hypothesis in schizophrenia patho-
physiology,2,3 the presence of GCLC high-risk genotypes 
in the control population suggests the possibility of a pro-
tective factor in healthy subjects carrying these variants.
Moreover, stratification of patients based on this 
genetic marker may help identifying distinct pathogenic 
mechanisms in GCLC low-risk vs high-risk schizophrenia 
patients. Indeed, in GCLC low-risk individuals [GlumPFC] 
are lower in patients as compared to controls, while it is 
not the case in GCLC high-risk genotypes (figure  3A). 
Furthermore, a positive correlation was found between 
[GlumPFC] and [GSHmPFC] in GCLC low-risk controls, but 
not in low-risk patients (figure 3B). This contrasts with 
GCLC high-risk genotypes, in which the tight correlation 
between [GSHmPFC] and [GlumPFC] is absent both in con-
trols and patients (figure 3C). However, the latter result 
was based on a small number of high-risk subjects; a rela-
tionship between brain GSH and Glu levels may emerge 
with a larger number of subjects. Together, these data sug-
gest that aberrant functions of enzymes in the γ-glutamyl 
cycle or other glutamatergic system impairments may be 
critical, at least in GCLC low-risk patients. Note that Glu 
and GSH were both quantified using water as an internal 
reference, therefore, water can be a potential driving fac-
tor in the correlation between GSH and Glu. However, 
such effect should be general for all groups, yet we did not 
see a correlation eg, in low-risk patients, suggesting that 
such an effect is likely of limited importance.
The present study did not reveal altered [GSHmPFC] 
in early psychosis patients and therefore contrasts with 
findings in patients with chronic schizophrenia.6 Apart 
from the genetic factor mentioned above, other hypoth-
eses can be mentioned (1) GSH measurement was per-
formed under resting conditions and alterations that can 
be reliably measured may only appear under particular 
conditions, such as psychological stress, which leads to 
oxidative stress at cellular levels.54 Indeed, lower [GSH] 
in fibroblasts of GCLC high-risk subjects as compared 
to low-risk genotypes were only observed under oxidative 
stress conditions, suggesting a deficit in the induction of 
regulatory mechanisms or adaptive responses. (2) GSH 
concentration determination by MRS does not allow the 
discrimination of GSH in the neuronal, glial or extracel-
lular pools.55 As [GSH] is about 10 times higher in astro-
cytes than in neurons, a differential neuronal regulation 
might be masked. (3) Early psychosis patients might have 
an intermediary phenotype between control subjects and 
patients with chronic schizophrenia. There could be a 
stage specificity for oxidative stress in the brain: altera-
tions of cerebral [GSH] might be more prominent in 
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chronic phase of the disease, while soluble superoxide 
dismutase-1 defects have recently been suggested to be an 
early phase marker.56 Importantly, our data indicates that 
medication and smoking are probably not biases, as we 
did not find a correlation between [GSHmPFC] and CPZ 
equivalents, and as a covariant smoking has no effects on 
[GSHmPFC] and the current results. Finally, there is a pos-
sibility that antipsychotics may have antioxidant effect 
and raise GSH to levels comparable to healthy controls. 
Indeed in the current study with early psychosis patients, 
the majority were medicated (20 out of 25) while in our 
previous study with chronic schizophrenia patients,6 only 
a minority were medicated (5 out of 14). The compari-
sons within studies of unmedicated to medicated patients 
are likely underpowered to detect a difference in brain 
GSH levels due to medication status. However, compari-
son of the 2 studies suggests that 2 key factors differed 
between them: illness phase (early vs chronic stage), as 
well as medication status. The medication effect on cere-
bral GSH levels thus requires further investigation.
Dysregulated GSH Redox Activity in Patients
Glutathione is critically involved in redox regulation: 
A  balanced activity of GPx to eliminate peroxides by 
metabolizing GSH and of GR to recycle GSH is crucial 
to maintain GSH homeostasis (supplementary figure 1s). 
Disturbed GSH redox coupling with the antioxidant 
defense system was suggested in the postmortem cau-
date, supported by the lack of correlations between GSH 
and GPx or GR in patients.7 Our study indicates similar 
defects of redox regulation in vivo in early psychosis (fig-
ure 4). In male subjects, blood GPx activities and brain 
GSH levels correlate negatively in patients (figure 4D), but 
positively in controls (figure 4A) with a significant differ-
ence between the 2 correlation coefficients. Similarly, we 
observed a trend of inverse correlation between blood 
GPx/GR enzymatic ratio and brain GSH levels in patients 
(figure 4F) but not in controls (figure 4C), with a signifi-
cant difference between the 2 correlation coefficients. On 
the other hand, blood GR activities and brain GSH levels 
were not correlated in both patients and controls. These 
correlation analyses of brain GSH levels with blood GPx 
and GPx/GR activities imply a proper regulation of the 
redox balance in controls and a disrupted redox homeo-
stasis in patients. Specifically, low brain GSH levels are 
associated with low peripheral oxidation status in controls 
but with high oxidation status in patients, as indicated by 
their high blood GPx activities, pointing to a dysregulated 
GSH homeostasis in early psychosis patients.
Lack of Link Between Peripheral and Central 
GSH Levels
The lack of relationship between [GSHB] and [GSHmPFC] is 
consistent with the reported lack of significant transport 
system for GSH across the blood brain barrier.57 Moreover 
peripheral GSH levels measurements showed large discrep-
ancies in the literature due to not only differences in ana-
lytical methodologies but also in testing materials (whole 
blood vs serum vs blood cells vs plasma), exposure to medi-
cation (drug naïve vs drug withdrawal vs medicated), stages 
of the disease (early psychosis vs chronic or active vs remis-
sion phase), lifestyle or dietary pattern.1 It is also important 
to note that blood GSH levels are susceptible to artefactual 
oxidation during preparation and longtime storage of sam-
ples, unless special care is taken to prevent it immediately 
after blood collection (such as scold conditions, thiol block-
ing reagents), which is difficult to guarantee in psychiatric 
clinical settings. To our knowledge, the present study is the 
first allowing a comparison between [GSHB] and [GSHmPFC], 
revealing that they are not correlated. This suggests that 
peripheral GSH levels unlikely reflects brain levels, in keep-
ing with Wu et al58 and the reported predominant liver ori-
gin of blood GSH.59,60 Raffa et  al10,11 reported decreased 
plasma GSH levels in drug naïve first episode patients. On 
the other hand, in the current study in which maximal care 
was taken to minimize artefactual factors during blood 
collection and processing, no difference was found in total 
blood GSH levels (blood cells plus plasma) of medicated 
patients in the EP vs matched controls. Indeed, GSH levels 
quantification in total blood was chosen instead of plasma 
levels as the latter are susceptible to more variability due to 
the interference of high intracellular GSH due to hemoly-
sis.61 In regards to relationship to GCLC genotypes, we did 
not observe differences in [GSHB] between long and short 
repeats, which may be ascribed to the fact that we assessed 
the free GSH instead of both free and protein bound GSH 
as measured in.50 This result is consistent with our previ-
ous study in patients with chronic schizophrenia61 showing 
no link between blood GSH levels and GCLC genotypes 
(unpublished data).
Limitations
This study has some limitations. Firstly, in line with 
most early psychosis studies, there were much less female 
patients in our cohort than males, which affects the gen-
erality of our results. Therefore further studies with more 
female patients are required for investigation of GSH 
redox regulation in female cohort. Secondly, considering 
GCLC high-risk subjects represent only about 30% of the 
patient population,14 it is challenging to recruit them in 
sufficient number to perform comparative studies with 
low risk genotype patients. Lastly, medication is a com-
mon confounding factor in studies conducted in patient 
samples, and although we did not observe differences in 
GSH levels between medicated and unmedicated patients, 
we can’t rule out an influence of medication on GSH lev-
els due to the small size of the sample. In addition, while 
the absence of a correlation between CPZ equivalents and 
GSH levels seem to exclude a correlation between these 2 
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variables, we can’t exclude an influence of medication on 
GSH levels at dosage below standard prescription; if  a 
ceiling effect were to exist for this correlation at a rela-
tively low CPZ dosage, it could very well not be observed 
in patients exposed to standard levels of medication. This 
issue needs therefore further investigation.
Conclusions
We show for the first time that GAG-TNR of GCLC 
gene affects [GSHmPFC], with high-risk genotypes associ-
ated with low [GSHmPFC]. These results extend to the cen-
tral nervous system previous results in fibroblasts15 and 
in red blood cells,50 therefore highlighting that GCLC 
genotypes should be taken into account for the investi-
gation of cerebral GSH levels in any pathology studies. 
Moreover, low [GSHmPFC] are associated to low peripheral 
oxidation status in controls but with high oxidation sta-
tus in patients, pointing to a dysregulated GSH homeo-
stasis in early psychosis patients and paving the way for 
the search of central and peripheral markers of the dis-
ease. Lastly, GCLC polymorphisms and disease associ-
ated correlations between [GlumPFC] and [GSHmPFC] may 
allow the stratification of patients and open new avenues 
to biomarker guided treatment strategies.
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